Product Datasheet

Tavapadon

Catalog No. **BP-01917** · CAS **1643489-24-0** · Form **free base** · Physical state **solid** · Color **White to light brown** · Version **1.0** · Revision **2026-09-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Dopamine Receptor	**Neurological Disease**

Molecular formula	**$C_{19}H_{16}F_3N_3O_3$**
Molecular weight	**391.3438**

STRUCTURE



DESCRIPTION

Tavapadon (PF-6649751; CVL-751; Rotation -) is an orally active and highly selective dopamine D1/D5 receptor partial agonist. Tavapadon is effective in enabling movement and reducing disability and has the potential for Parkinson's disease.

BIOLOGICAL ACTIVITY

In Vivo

Tavapadon (PF-06649751; 0.02 and 0.04 mg/kg; s.c.) at the 0.04 mg/kg test dose increases locomotor activity, whereas the 0.02 mg/kg dose has little or no effect.

Tavapadon (0.04 mg/kg, s.c.) also improves parkinsonian disability scores with the maximal improvement observed at 110 min after drug administration.

Higher doses of Tavapadon (0.1 and 0.15 mg/kg; s.c.) leads to statistically significant improvement relative to vehicle in locomotor activity.

Tavapadon (0.1 mg/kg; s.c.) has the mean maximal unbound plasma concentration of 8 nM and achieves 3 hours after compound administration in captive-bred macaques.

SOLUBILITY

Soluble in DMSO, not in water

REFERENCES

[1]. Young D, et al. D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited DyskinesiaSide Effects. ACS Chem Neurosci. 2020 Feb 19;11(4):560-566.